内科

目的观察低分子肝素钙与普米克令舒联合吸入治疗慢性阻塞性肺疾病急性加重期（AECOPD）的疗效。方法AECOPD病人98例，按随机数分配法分为治疗组52例，对照组46例，两组病人均给予常规治疗，治疗组在常规治疗的基础上加用低分子肝素钙联合普米克令舒吸入治疗。观察治疗前后以及组间临床症状改善情况，各项指标的变化。结果两组临床症状评分、平均住院日比较差异有统计学意义（P均＜0.05），治疗组临床疗效明显优于对照组，差异有统计学意义（u=2.692，P=0.007）。治疗后两组血气分析、肺功能均比治疗前改善，差异有统计学意义（P＜0.01），治疗组改善程度大于对照组，差异有统计学意义（P＜0.05）。结论低分子肝素钙与普米克令舒联合吸入治疗AECOPD，临床疗效确切，值得推广应用。

ObjectiveTo observe the efficacy of low molecular weight heparin calcium combined with Pulmicort respules in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods98 patients were randomly divided into treatment group(n=52) and control group (n=46).Patients of the two groups were treated with conventional therapy.In the treatment group,low molecular weight heparin calcium and Pulmicort respules were added in the therapy.The changes of indicators and clinical symptoms were observed between the two groups before and after treatment.ResultsCompared with the control group,there was significant difference in the clinical symptom scores,the average days of hospitalization(all P＜0.05),the efficacy of treatment group was better than control group(u=2.692,P=0.007).Before and after treatment,there were significant efficacy in blood gas analysis and lung function in both groups(P＜0.01),and there was significant difference in blood gas analysis and lung function between the two groups(P＜0.05),but the range of promotion are bigger in treatment group.ConclusionsThe clinical therapeutic effect is exact in the treatment of AECOPD using low molecular weight heparin calcium and inhalation Pulmicort respules,so application and dissemination is worthy.